Coronavirus: Thread

[grarpamp]

Groundbreaking Israeli Study Shows How COVID Proteins Attack The Heart
And Blood Vessels

https://www.jpost.com/health-and-wellness/coronavirus/why-is-covid-causing-vascular-damage-israeli-study-offers-answers-683937

Earlier Thursday morning, we shared a report about a strange
phenomenon unfolding at hospitals and emergency rooms across the US.
Even as COVID cases continue to fall, emergency rooms across the
country have become absolutely packed with patients seeking treatment
for abdominal pain, blood clots, heart conditions and respiratory
problems. All of these symptoms line up with the wide range of
official COVID symptoms reported by the CDC. But, as the news reports
state, the cause of this sudden wave, which has led to some patients
being treated again in hospital hallways, remains officially unclear.

More than 18 months after it first emerged from Wuhan, SARS-CoV-2, the
virus that causes COVID, remains an enigma to scientists, who have
been conducting a wide range of studies to try and learn more about
how the virus does what it does. One of COVID's most notable features
is its ability to cause damage not just to patient's respiratory
system, but to the heart and vascular system as well. Oftentimes, this
damage leaves patients with long-lasting symptoms that persist well
beyond the initial infection.

Even before it became the first nation on the planet to vaccinate
nearly its entire population (it has been doling out booster jabs
since August), Israel has been a leading source of COVID-related
research. And the latest pioneering study produced by researchers from
a range of disciplines (from epidemiology to computer science) at Tel
Aviv University certainly raises some interesting questions, according
to a report in the Jerusalem Post.

The researchers have become the first on earth to identify which 5 of
the 29 proteins that form the SARS-CoV-2 virus are responsible for
damaging patients' blood vessels'

    ...[A] team of Tel Aviv University researchers have identified the
five proteins of the 29 that form the virus which are responsible for
damaging blood vessels.

    "We see a very high incidence of vascular disease and blood
clotting, for example, stroke and heart attack among COVID patients,"
says Dr. Ben Maoz, lead author of the study published in the journal
eLife.

    "We tend to think of COVID as primarily a respiratory disease but
the truth is that coronavirus patients are up to three times more
likely to have a stroke or heart attack,” he added. “All the evidence
shows that the virus severely damages the blood vessels or the
endothelial cells that line the blood vessels. However, to this day,
the virus has been treated as one entity. We wanted to find out which
proteins in the virus are responsible for this type of damage."

The study was carried out using novel methods: researchers came
together to insert different sequences of viral RNA into human blood
vessels in a lab, and observed the reaction. In this manner, they were
able to deduce which proteins caused the most damage to tissue from
the vascular system. In particular, they found which proteins are
responsible for doing the most damage to the human vascular system.

    "When the coronavirus enters the body, it begins to produce 29
proteins, a new virus is formed, then that virus produces 29 new
proteins, and so on," Maoz said.

    "In this process, our blood vessels turn from opaque tubes into
kind of permeable nets or pieces of cloth, and in parallel there is an
increase in blood clotting. We thoroughly examined the effect of each
of the 29 proteins expressed by the virus, and were successful in
identifying the five specific proteins that cause the greatest damage
to endothelial cells and hence to vascular stability and function."

To help model and verify its findings, the team used computational
models to discern exactly which proteins had the greatest impact on
the human tissue.

As the scientists said the hope is that this insight will help
humanity develop a better understanding of how the virus causes so
much damage to the heart and blood vessels.

    "Our research could help find targets for a drug that will be used
to stop the virus’s activity, or at least minimize damage to blood
vessels."

But, what if it instead raises questions about the vaccines scientists
have developed, which rely on viral RNA to "reprogram" the human
immune system?







Pfizer Vax Trial Being Probed After Whistleblower Exposes 'Falsified
Data', According To Contractor

https://www.theepochtimes.com/report-of-problems-with-pfizer-covid-19-vaccine-trial-being-investigated-contract-company_4085813.html
https://www.theepochtimes.com/approved-version-of-pfizers-covid-19-vaccine-still-not-available-in-us_4046513.html
https://redica.com/pharma-desk-inspections-missed-action-dates-take-place-of-fda-in-person-site-visits/

The alleged problems with a major clinical trial examining Pfizer’s
COVID-19 vaccine trial are being probed, a contract company involved
in the research has confirmed.

Ventavia Research Group operated several of the trial sites in the
fall of 2020. Brook Jackson worked for the company during this time.
She told the British Medical Journal (BMJ) that the trial was riddled
with issues, including the falsification of data.

Jackson said she alerted the Food and Drug Administration (FDA) to the
problems she witnessed and was fired within hours of doing so.

Ventavia confirmed to The Epoch Times that it employed Jackson for two
weeks last year.

Lauren Foreman, director of business development and communications,
said in an email that Ventavia is investigating the allegations from
Jackson.

“Ventavia takes research compliance, data integrity, and participant
safety very seriously and stands behind its important work supporting
the development of lifesaving vaccines and is conducting its
investigation accordingly,” she said.

The FDA appeared to confirm it was aware of the matter.

“Although the agency cannot comment further at this time in this
ongoing matter, FDA has full confidence in the data that were used to
support the Pfizer-BioNTech COVID-19 vaccine authorization and the
Comirnaty approval,” a spokeswoman told The Epoch Times in an email.

Ventavia worked on the trial that led to emergency use authorization
(EUA) for Pfizer’s jab. The FDA later approved the shot, though many
or all of the doses being administered in the United States continue
to be the EUA-version.

Pfizer did not immediately respond to a request for comment.

Jackson, who worked with clinical trials for over 15 years, told the
BMJ she repeatedly raised concerns with her superiors about what she
was witnessing, including patient safety concerns. She began to feel
her reports were being ignored and began taking photographs using her
phone. One photograph apparently showed that needles were discarded in
a plastic bag instead of a box, while another was said to have showed
packaging materials that revealed trial participants’ identification
numbers, signaling they may have been unblinded.

Jackson listed 12 concerns she had in a Sept. 25 message to the FDA,
including participants not being monitored after receiving an
injection and vaccines not being stored at proper temperatures. She
also alleged that Ventavia staff members were targeted by higher-ups
for reporting problems.

Jackson said the FDA sent her an email acknowledging receipt of the
list and she received a call from an FDA inspector, but has heard
nothing from the agency since then.

The Epoch Times has submitted a Freedom of Information Act request
concerning Jackson’s email to the FDA and internal communications from
the agency regarding the message.

The FDA said in August it inspected nine of the trial’s 153 sites.
None of Ventavia’s sites were inspected.

The inspections were limited “because the study was ongoing, and the
data required for verification and comparison were not yet available
to the IND [investigational new drug],” an FDA officer wrote in a
summary of the inspections.

Some pharmaceutical companies have seen inspections waived or FDA
officials deciding to conduct an inspection remotely, Philip Crooker,
technical vice president of Paraexel, told a forum in December 2020.
Inspections of domestic sites plunged from 13,001 in 2019 to 6,574 in
2020, according to FDA data.